https://orcid.org/0000-0001-9339-777X
References
- Sato K, Ishii T, Kaise T. Burden of asthma in elderly Japanese patients: Using hospital-based administrative claims data. Pulm Ther 2020;6(2):247–260.
- Skloot GS, Busse PJ, Braman SS, Kovacs EJ, Dixon AE, Vaz Fragoso CA, Scichilone N, Prakash YS, Pabelick CM, Mathur SK, et al.; ATS Ad Hoc Committee on Asthma in the Elderly. An Official American Thoracic Society Workshop report: Evaluation and management of asthma in the elderly. Ann Am Thorac Soc 2016;13(11):2064–2077.
- Dunn RM, Busse PJ, Wechsler ME. Asthma in the elderly and late-onset adult asthma. Allergy 2018;73(2):284–294. doi:10.1111/all.13258.
- Pasha MA, Sundquist B, Townley R. Asthma pathogenesis, diagnosis, and management in the elderly. Allergy Asthma Proc 2017;38(3):184–191. doi:10.2500/aap.2017.38.4048.
- Moorman JE, Akinbami LJ, Bailey CM. National surveillance of asthma: United States, 2001-2010. Vital Health Stat 2012;35:1–58.
- Bozek A, Jarzab J. Adherence to asthma therapy in elderly patients. J Asthma 2010;47(2):162–165. doi:10.3109/02770900903497204.
- Plaza V, López-Viña A, Entrenas LM, Fernández-Rodríguez C, Melero C, Pérez-Llano L, Gutiérrez-Pereyra F, Tarragona E, Palomino R, Cosio BG, et al. Differences in adherence and non-adherence behaviour patterns to inhaler devices between COPD and asthma patients. COPD 2016;13(5):547–554.
- Global Initiative for Asthma. 2020. Global Strategy for Asthma Management and Prevention. Main report. Available from: www.ginasthma.org.
- Busse WW. Biological treatments for severe asthma: A major advance in asthma care. Allergol Int 2019;68(2):158–166. doi:10.1016/j.alit.2019.01.004.
- Lieberman PL, Umetsu DT, Carrigan GJ, Rahmaoui A. Anaphylactic reactions associated with omalizumab administration: Analysis of a case-control study. J Allergy Clin Immunol 2016;138(3):913–915.e2.
- Adachi M, Kozawa M, Yoshisue H, Lee Milligan K, Nagasaki M, Sasajima T, Miyamoto T, Ohta K. Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan. Respir Med 2018;141:56–63.
- Rodenburg EM, Stricker BHC, Visser LE. Sex-related differences in hospital admissions attributed to adverse drug reactions in the Netherlands. Br J Clin Pharmacol 2011;71(1):95–104.
- Vennera M del C, Picado C, Herráez L, Galera J, Casafont J. Factors associated with severe uncontrolled asthma and the perception of control by physicians and patients. Arch Bronconeumol 2014;50(9):384–391. doi:10.1016/j.arbr.2014.06.017.
- Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, Martinot J-B, Sagara H, Albers FC, Bradford ES, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med 2017;377(17):1613–1629. doi:10.1056/NEJMoa1708208.
- Maltby S, Gibson PG, Powell H, McDonald VM. Omalizumab treatment response in a population with severe allergic asthma and overlapping COPD. Chest 2017;151(1):78–89. doi:10.1016/j.chest.2016.09.035.
- Tat TS, Cilli A. Evaluation of long-term safety and efficacy of omalizumab in elderly patients with uncontrolled allergic asthma. Ann Allergy Asthma Immunol. 2016;117(5):546–549.
- Maykut RJ, Kianifard F, Geba GP. Response of older patients with IgE-mediated asthma to omalizumab: a pooled analysis. J Asthma 2008;45(3):173–181. doi:10.1080/02770900701247277.
- Agache I, Beltran J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW, Casale T, Chivato T, Corren J, Del Giacco S, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma. Allergy 2020;75(5):1023–1042.
- Rial MJ, Valverde M, Del Pozo V, González-Barcala FJ, Martínez-Rivera C, Muñoz X, Olaguibel JM, Plaza V, Curto E, Quirce S, et al. Clinical characteristics in 545 patients with severe asthma on biological treatment during the COVID-19 outbreak. J Allergy Clin Immunol Pract 2021;9(1):487–489 e1.